TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00165919

Intervention type: OTHER
Intervention: None. Not a clinical trial. Specimens taken for basic research in laboratory.
Study: NCT03092167

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physical exercises
Description: Physical exercises
Study: NCT02385760

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CTX-4430

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT04202705

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SYD1875
Description: SYD1875 IV (in the vein) infusion every three weeks. Number of cycles: until cancer progression or unacceptable toxicity develops. Different doses.
Study: NCT03807830

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Electrocochlography
Description: Intra-operative ECochG recording via the implant, post operative ECochG measurements. Impedances measured over time.
Study: NCT00530348

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Alemtuzumab
Description: Alemtuzumab 12 milligram (mg) per day intravenous (IV) infusion on 5 consecutive days at Month 0, followed by alemtuzumab 12 mg per day IV infusion on 3 consecutive days at Month 12.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Interferon beta-1a
Description: Interferon beta-1a 44 microgram (mcg) subcutaneously 3-times weekly for 24 months. Dose adjustment was done as per Investigator's discretion.
Study: NCT03256149

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal saline (IV placebo)
Study: NCT00457964

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RAD001
Description: 5 and 10 mg/day or 30, 50, 70mg/week
Study: NCT02855515

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Short-time diagnostic anaesthesia
Description: Patients will undergo a short-time general anaesthesia in order to diagnose Obstructive Sleep Apnoea when relaxed.
Study: NCT01747018

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Platelet-rich Plasma
Study: NCT02699216

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electrical Stimulation of the Retina
Description: Transpalpebral micro-current electrical stimulation treatment for 3 consecutive days followed by a short wash-out period of 2 days.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Electrical Stimulation of the Retina
Description: Transpalpebral micro-current electrical stimulation treatment for 3 consecutive days followed by a short wash-out period of 2 days.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electrical Stimulation of the Retina
Description: Transpalpebral micro-current electrical stimulation treatment for 3 consecutive days followed by a short wash-out period of 2 days.
Study: NCT03169751

Intervention type: DEVICE
Intervention: Brain Sentinel Monitoring and Alerting System
Description: The Brain Sentinel Monitoring and Alerting System is indicated for use as an adjunct to seizure monitoring in adults in the home or healthcare facilities during periods of rest. The device is to be used on the belly of the biceps muscle to analyze surface electromyographs (sEMG) signals that may be associated with generalized tonic-clonic (GTC) seizures and to provide an alarm to alert caregivers of unilateral, appendicular, tonic extension that could be associated with a GTC seizure. The System records and stores sEMG data for subsequent review by a trained healthcare professional.

Intervention type: DEVICE
Intervention: Brain Sentinel Monitoring and Alerting System
Description: The Brain Sentinel Monitoring and Alerting System is indicated for use as an adjunct to seizure monitoring in adults in the home or healthcare facilities during periods of rest. The device is to be used on the belly of the biceps muscle to analyze surface electromyographs (sEMG) signals that may be associated with generalized tonic-clonic (GTC) seizures and to provide an alarm to alert caregivers of unilateral, appendicular, tonic extension that could be associated with a GTC seizure. The System records and stores sEMG data for subsequent review by a trained healthcare professional.
Study: NCT03371771

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Volunteer-delivered Behavioral Activation
Description: Behavioral Activation as delivered by trained volunteers

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: MSW-delivered Behavioral Activation
Description: Behavioral Activation as delivered by trained MSWs
Study: NCT01897376

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Pfannenstiel incision
Description: Pfannenstiel incision at time of cesarean section

Intervention type: PROCEDURE
Group type: OTHER
Intervention: vertical skin incision
Description: vertical skin incision at time of cesarean section
Study: NCT01415739

Intervention type: OTHER
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT06693349

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: the effect of platelet-rich fibrin in treatment of contaminated and uncontaminated immature permanent teeth
Description: this procedure was anticipated to give superior effects than other procedure used in this study

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: the effect of apexification in treatment of contaminated and uncontaminated immature permanent teeth
Description: this procedure was anticipated to be replaced by other procedure be used in this study
Study: NCT03399747

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abb-R-CHOP
Description: Completely Excised LocalizedGastrointestinal CD20 (+) Diffuse Large B-cell Lymphoma~3 Cycles(1 Cycle:4weeks) of Rituximab Plus CHOP (Cyclophosphamide, Adriamycin, Vincristine, and Prednisolone) Immunochemotherapy
Study: NCT04437823

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Intravenous Infusions of Stem Cells
Description: Cultured stem cells will be injected at days 1, 3 and 5 intravenously. While patients will be monitored and evaluated for various hematological and organ functions at baseline (day 0) and days 1, 3, 5, 7, 14, 21 and 30
Study: NCT03662529

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Four-Session Mind Freedom Plan
Description: Problem-solving-focused individualized cognitive behavioral therapy (CBT) that featured homework-worksheets to reinforce session-concepts.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual therapy
Description: Therapy was mostly supportive therapy with an emphasis problem solving on increasing veteran motivation. A discussion of the antecedents to relapse would take place if a relapse occurred and coping skills were discussed and reviewed.
Study: NCT02621853

Intervention type: DEVICE
Group type: OTHER
Intervention: Raman spectroscopy of the liver
Description: Liver will be illuminated by the Raman spectroscope optic probe in order to assess fat content
Study: NCT03654326

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gefapixant
Description: Gefapixant tablet 45 mg taken orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo matching gefapixant tablet taken orally
Study: NCT06693349

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: the effect of apexification in treatment of contaminated and uncontaminated immature permanent teeth
Description: this procedure was anticipated to be replaced by other procedure be used in this study
Study: NCT03654326

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matching gefapixant tablet taken orally
Study: NCT04194216

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intra-operative single intravenous(iv) dose of cephalexin 2 g or clindamycin 900 mg.
Description: Treatment Arm A
Study: NCT03654326

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naproxen
Description: Naproxen sodium 275 mg tablets taken orally as needed, at dose prescribed by sites' principal investigator

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Naproxen
Description: Naproxen sodium 275 mg tablets taken orally as needed, at dose prescribed by sites' principal investigator
Study: NCT04194216

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intra-operative single dose (iv) of cephalexin 2 g or clindamycin 900 mg and postoperative oral dose of cephalexin 250mg (every 4 hours) or clindamycin 150mg(every 6 hours) for 3 days
Description: Treatment Arm B
Study: NCT02448342

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Remote Dielectric Sensing (ReDS) Wearable System
Description: The ReDS device provides noninvasive measurement of lung fluid content. It comprises a wearable vest with embedded sensors and a bedside console, with touch-screen display. A measurement reading is provided within 90sec. Results are shared with the treating physician via a secured web portal.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Remote Dielectric Sensing (ReDS) Wearable System
Description: The ReDS device provides noninvasive measurement of lung fluid content. It comprises a wearable vest with embedded sensors and a bedside console, with touch-screen display. A measurement reading is provided within 90sec. Results are shared with the treating physician via a secured web portal.
Study: NCT01834482

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Modified Atkins diet
Description: Patients will receive the modified Atkins diet with a 20 gram per day carbohydrate limit and encouragement to consume plenty of fat and eat to satiety.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Modified Atkins diet
Description: Patients will receive the modified Atkins diet with a 20 gram per day carbohydrate limit and encouragement to consume plenty of fat and eat to satiety.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: KetoCal
Description: Patients will receive a KetoCal 4:1 ratio (fat: carbohydrates and protein) liquid daily for the first month (if randomized to this arm of the study). They will also be started on the modified Atkins diet.
Study: NCT03803943

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parent-Implemented Communication Intervention (PICT)
Description: Weekly hour long intervention sessions for 6 months

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: No Intervention - Business-as-usual control
Description: Does not receive PICT internvention
Study: NCT03626662

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 890
Description: Ascending Single Doses of AMG 890

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Calculated volume to match experimental drug.
Study: NCT05826301

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Percutaneous neuromodulation in tibial nerve
Description: The procedure consisted in the application of a square wave biphasic electrical current, with 2-4 Hz frequency, 450 μs pulse during 25 minutes with a needle (0.30mm x 40 mm) inserted proximal to the surface on the tibial nerve.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous electrolysis
Description: The procedure consist on placed a needle (0.30mm x 40 mm) on the most hyperalgesic plantar fascia location with a galvanic current of 3mA, 3 times during 3 seconds.~1 time per weeK
Study: NCT03213548

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Alar facial groove incision
Description: All procedures related to alterations in the alar base will be based on an algorithm proposed by 2010 Adamnson et al lar Soft-Tissue Techniques in Rhinoplasty Algorithmic Approach, Quantifiable Guidelines, and Scar Outcomes From a Single Surgeon Experience ,published at Archives Facial Plastic Surgery in which a sequential approach is used, evaluating step-by-step surgical needs. Initially, the alar base can be reduced by removing tissue from the nasal sill. At this step, modifications at the shape or the width of the nostrils can be done. After that, a rotation-advancement flap is made, and the sill defect is closed. The nasal flair is then assessed and tissue from the alar border can be removed if needed. The incisions not spare the alar facial groove.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Alar facial groove spared
Description: The technique is the same of the Alar facial groove incision intervention group, but the incisions spare the groove. The incisions will be at 1 mm above the groove.
Study: NCT04142658

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apixaban 5 MG
Description: For patients that do NOT meet the following criteria~* age ≥ 80 years~* weight ≤ 60 kilograms~* creatinine ≥ 1.5 mg/dL (133 micromol/L)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apixaban 2.5 MG
Description: For patients that meet at least 2 of the following criteria~* age ≥ 80 years~* weight ≤ 60 kilograms~* creatinine ≥ 1.5 mg/dL (133 micromol/L)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Warfarin
Description: Active Control Intervention
Study: NCT03844815

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: Decitabine will be administered intravenously at a dose of 20mg per day for 10 days during Cycle 1 (28 day cycle)~Decitabine will be administered intravenously at a dose of 20mg per day for 10 days of Cycle 2 (28 day cycle).~Decitabine will be administered intravenously at a dose of 20mg per day for 5 days of each 28 day maintenance cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Venetoclax administered orally on days 1-21 of cycle 1, cycle 2 and maintenance (28 day cycles). Dose levels will be assigned at time of enrollment anywhere from 100mg-400mg. Dose escalation will follow the 3+3 study design.
Study: NCT01613196

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography with 18F-Fluoro-deoxy-glucose
Description: 2 or 3 FDG-PET scans will be performed in all patients : at inclusion\*, end of treatment and 6 months after completion of treatment in cases of persistent uptake~\*except if already done in the last 15 days.
Study: NCT06641440

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: patients will be treated for three months in the two groups with the two different protocols for three months both

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: patients will be treated for three months in the two groups with the two different protocols for three months both
Study: NCT03495635

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Big Brothers Big Sisters Community-Based Mentoring Program
Description: One-to-one mentoring provided by an adult volunteer with training and ongoing monitoring and support from program staff.
Study: NCT04769778

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valsartan 80Mg Oral Tablet
Description: treatment with 80mg /day of valsartan
Study: NCT04589312

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care vaccines
Description: Visit 1: Check tetanus immunisation status. Vaccination up to 25+ 6 weeks of pregnancy with Td; Visit 2: vaccination at least 4 weeks after visit 2 with either Tdap or Td (per randomisation and according to WHO guidance)

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care vaccines
Description: Visit 1: Check tetanus immunisation status. Vaccination up to 25+ 6 weeks of pregnancy with Td; Visit 2: vaccination at least 4 weeks after visit 2 with either Tdap or Td (per randomisation and according to WHO guidance)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Boostagen, (BioNet-Asia)
Description: Visit 1: Check tetanus immunisation status. Vaccination up to 25+ 6 weeks of pregnancy with Td; Visit 2: vaccination at least 4 weeks after visit 2 with either Tdap or Td (per randomisation and according to WHO guidance);

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Boostagen, (BioNet-Asia)
Description: Visit 1: Check tetanus immunisation status. Vaccination up to 25+ 6 weeks of pregnancy with Td; Visit 2: vaccination at least 4 weeks after visit 2 with either Tdap or Td (per randomisation and according to WHO guidance);
Study: NCT02139800

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sustained Inflation
Description: The first sustained inflation will use inflation pressure of 20 cm H20 for 15 seconds
Study: NCT01225224

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: peficitinib
Description: oral
Study: NCT02139800

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Newborn Resuscitation Program (NRP) Guidelines using a standard PEEP/CPAP of 5-7 cm H2O as compared to the Sustained Inflation intervention
Study: NCT01225224

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: peficitinib
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: peficitinib
Description: oral

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral
Study: NCT01409200

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antiandrogen Therapy
Description: Given per standard of care

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antiandrogen Therapy
Description: Given per standard of care

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Axitinib
Description: Given PO

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radical Prostatectomy
Description: Undergo radical prostatectomy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Radical Prostatectomy
Description: Undergo radical prostatectomy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Regional Lymph Node Dissection
Description: Undergo pelvic lymph node dissection

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Regional Lymph Node Dissection
Description: Undergo pelvic lymph node dissection
Study: NCT05533476

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multi Sensory Stimulation and Priming
Description: In the MuSSAP intervention group, the infant wears a multisensory stimulating wristband aiming at increasing attention for the affected upper limb and readiness to initiate a goal-directed movement. Parents are instructed to present a toy to their child if the child shows attention to the affected arm and hand. Upper extremity motor activities like reaching, grasping and holding are practiced. Parents practice daily and once a week the training will be guided or conducted by a physical or occupational therapist in the home environment. An occupational therapist from the rehabilitation center will coach parents during the intervention period through the internet, by means of analyzing the videos from the home training.
Study: NCT03850574

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tuspetinib
Description: Daily (QD), continuous dosing

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tuspetinib
Description: Daily (QD), continuous dosing

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tuspetinib
Description: Daily (QD), continuous dosing
Study: NCT05533476

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intensive Usual Care (Upper Limb)
Description: The Intensive Usual Care (Upper Limb) intervention is a more intensive (in duration and frequency) version of standard Usual Care with focus on the motor development of the affected upper extremity. Upper extremity motor activities like reaching, grasping and holding are practiced. Parents practice daily and once a week the training will be guided or conducted by a physical or occupational therapist in the home environment. An occupational therapist from the rehabilitation center will coach parents during the intervention period through the internet, by means of analyzing the videos from the home training.
Study: NCT05270421

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Furosemide 40 mg
Description: Standard ESWL + Furosemide 40 mg
Study: NCT03850574

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tuspetinib
Description: Daily (QD), continuous dosing

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tuspetinib
Description: Daily (QD), continuous dosing

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax Oral Tablet
Description: Venetoclax will be given to study participants in the Part C tuspetinib plus venetoclax combination treatment group either in 50 mg or 100 mg tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax Oral Tablet
Description: Venetoclax will be given to study participants in the Part C tuspetinib plus venetoclax combination treatment group either in 50 mg or 100 mg tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine for Intravenous Infusion
Description: Azacitidine will be given to study participants in Part D as intravenous infusion at a dose of 75 mg/m\^2
Study: NCT05270421

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Treatment
Description: Standard ESWL

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional Treatment
Description: Standard ESWL
Study: NCT01180530

Intervention type: DEVICE
Intervention: NovoPen Echo®
Description: Prescribed insulin treatment delivered by NovoPen Echo®
Study: NCT04231318

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cingal
Description: Single intra-articular injection of Cingal into the knee.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triamcinolone Hexacetonide (TH)
Description: Single intra-articular injection of TH into the knee.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single intra-articular injection Placebo (0.9% Saline) into the knee.
Study: NCT00381381

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donepezil
Description: 2.5mg once daily for the first 7 days, 5mg once daily for the next 3 weeks, after then the dose can be increased 10mg once daily under the investigator's decision.
Study: NCT04246736

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Bädda för Kvalitet
Description: A group-administered preventive programme focusing on beneficial strategies for sleep and recuperation, in relation to work related stress and shift work. The intervention was based on knowledge from previous research on sleep, stress and work hours, as well as on cognitive behavioural therapy (CBT) techniques for sleep and stress management, modified for shift workers. Participants were encouraged to discuss and reflect on personal habits related to sleep and recovery. As homework between sessions, the participants were encouraged to try possibly beneficial strategies for sleep and recuperation. All participants got written material covering the content of the session, during each sessions. In addition, an adapted version of a biomathematical model (ArturNurse) was used to give participants an estimation of expected sleep lengths and fatigue levels together with tips of possible strategies to optimise sleep in relation to different shifts.